Does the media prefer PLRX or MGNX?

In the previous week, MacroGenics had 2 more articles in the media than Pliant Therapeutics. MarketBeat recorded 5 mentions for MacroGenics and 3 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 1.08 beat MacroGenics' score of 0.37 indicating that Pliant Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pliant Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MacroGenics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, GLSI or PLRX?

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Greenwich LifeSciences N/A N/A -$19.36M -$1.57 N/A Pliant Therapeutics N/A N/A -$149.34M -$1.84 N/A

Is GLSI or PLRX more profitable?

Pliant Therapeutics' return on equity of -58.11% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets Greenwich LifeSciences N/A -941.15% -368.53% Pliant Therapeutics N/A -58.11% -44.37%

Does the media refer more to GLSI or PLRX?

In the previous week, Greenwich LifeSciences had 16 more articles in the media than Pliant Therapeutics. MarketBeat recorded 19 mentions for Greenwich LifeSciences and 3 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 1.08 beat Greenwich LifeSciences' score of 0.77 indicating that Pliant Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Greenwich LifeSciences 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Pliant Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, ALXO or PLRX?

ALX Oncology is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALX Oncology N/A N/A -$101.69M -$1.49 N/A Pliant Therapeutics N/A N/A -$149.34M -$1.84 N/A

Is ALXO or PLRX more profitable?

Pliant Therapeutics' return on equity of -58.11% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets ALX Oncology N/A -124.06% -85.57% Pliant Therapeutics N/A -58.11% -44.37%

Does the media refer more to ALXO or PLRX?

In the previous week, ALX Oncology and ALX Oncology both had 3 articles in the media. Pliant Therapeutics' average media sentiment score of 1.08 beat ALX Oncology's score of 0.97 indicating that Pliant Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pliant Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NAGE or PLRX?

In the previous week, Pliant Therapeutics had 1 more articles in the media than Niagen Bioscience. MarketBeat recorded 3 mentions for Pliant Therapeutics and 2 mentions for Niagen Bioscience. Pliant Therapeutics' average media sentiment score of 1.08 beat Niagen Bioscience's score of 0.94 indicating that Pliant Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Niagen Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pliant Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SRZN or PLRX?

In the previous week, Surrozen and Surrozen both had 3 articles in the media. Pliant Therapeutics' average media sentiment score of 1.08 beat Surrozen's score of 0.63 indicating that Pliant Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Surrozen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pliant Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Pliant Therapeutics (PLRX) Competitors

$1.09 +0.01 (+0.93%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$1.09 0.00 (0.00%)

As of 07/24/2026 07:34 PM Eastern

Compare

PLRX vs. MGNX, GLSI, ALXO, NAGE, and SRZN

Should you buy Pliant Therapeutics stock or one of its competitors? MarketBeat compares Pliant Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pliant Therapeutics include MacroGenics (MGNX), Greenwich LifeSciences (GLSI), ALX Oncology (ALXO), Niagen Bioscience (NAGE), and Surrozen (SRZN). These companies are all part of the "pharmaceutical products" industry.

How does Pliant Therapeutics compare to MacroGenics?

Pliant Therapeutics (NASDAQ:PLRX) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

97.3% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 8.7% of Pliant Therapeutics shares are owned by insiders. Comparatively, 13.6% of MacroGenics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

MacroGenics has higher revenue and earnings than Pliant Therapeutics. MacroGenics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	N/A	N/A	-$149.34M	-$1.84	N/A
MacroGenics	$157.08M	1.50	-$74.62M	-$1.10	N/A

Pliant Therapeutics has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market. Comparatively, MacroGenics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

Pliant Therapeutics has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. Pliant Therapeutics' return on equity of -58.11% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-58.11%	-44.37%
MacroGenics	-44.79%	-147.80%	-28.40%

Pliant Therapeutics presently has a consensus price target of $3.00, suggesting a potential upside of 175.23%. MacroGenics has a consensus price target of $5.50, suggesting a potential upside of 48.65%. Given Pliant Therapeutics' higher probable upside, research analysts plainly believe Pliant Therapeutics is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, MacroGenics had 2 more articles in the media than Pliant Therapeutics. MarketBeat recorded 5 mentions for MacroGenics and 3 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 1.08 beat MacroGenics' score of 0.37 indicating that Pliant Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pliant Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MacroGenics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

MacroGenics beats Pliant Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Pliant Therapeutics compare to Greenwich LifeSciences?

Greenwich LifeSciences (NASDAQ:GLSI) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Greenwich LifeSciences has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.

Greenwich LifeSciences presently has a consensus target price of $57.00, indicating a potential upside of 339.14%. Pliant Therapeutics has a consensus target price of $3.00, indicating a potential upside of 175.23%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Greenwich LifeSciences is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Pliant Therapeutics' return on equity of -58.11% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-941.15%	-368.53%
Pliant Therapeutics	N/A	-58.11%	-44.37%

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A
Pliant Therapeutics	N/A	N/A	-$149.34M	-$1.84	N/A

In the previous week, Greenwich LifeSciences had 16 more articles in the media than Pliant Therapeutics. MarketBeat recorded 19 mentions for Greenwich LifeSciences and 3 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 1.08 beat Greenwich LifeSciences' score of 0.77 indicating that Pliant Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Greenwich LifeSciences	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Pliant Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

4.2% of Greenwich LifeSciences shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 51.5% of Greenwich LifeSciences shares are held by insiders. Comparatively, 8.7% of Pliant Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Greenwich LifeSciences beats Pliant Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Pliant Therapeutics compare to ALX Oncology?

ALX Oncology (NASDAQ:ALXO) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

ALX Oncology has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market.

In the previous week, ALX Oncology and ALX Oncology both had 3 articles in the media. Pliant Therapeutics' average media sentiment score of 1.08 beat ALX Oncology's score of 0.97 indicating that Pliant Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pliant Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ALX Oncology currently has a consensus price target of $4.60, indicating a potential upside of 126.60%. Pliant Therapeutics has a consensus price target of $3.00, indicating a potential upside of 175.23%. Given Pliant Therapeutics' higher possible upside, analysts plainly believe Pliant Therapeutics is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 21.0% of ALX Oncology shares are held by company insiders. Comparatively, 8.7% of Pliant Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Pliant Therapeutics' return on equity of -58.11% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-124.06%	-85.57%
Pliant Therapeutics	N/A	-58.11%	-44.37%

ALX Oncology is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A
Pliant Therapeutics	N/A	N/A	-$149.34M	-$1.84	N/A

Summary

ALX Oncology and Pliant Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Pliant Therapeutics compare to Niagen Bioscience?

Niagen Bioscience (NASDAQ:NAGE) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are owned by institutional investors. 10.0% of Niagen Bioscience shares are owned by insiders. Comparatively, 8.7% of Pliant Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Pliant Therapeutics had 1 more articles in the media than Niagen Bioscience. MarketBeat recorded 3 mentions for Pliant Therapeutics and 2 mentions for Niagen Bioscience. Pliant Therapeutics' average media sentiment score of 1.08 beat Niagen Bioscience's score of 0.94 indicating that Pliant Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Niagen Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pliant Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Niagen Bioscience currently has a consensus target price of $10.50, indicating a potential upside of 227.10%. Pliant Therapeutics has a consensus target price of $3.00, indicating a potential upside of 175.23%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, equities research analysts plainly believe Niagen Bioscience is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Niagen Bioscience has higher revenue and earnings than Pliant Therapeutics. Pliant Therapeutics is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$129.42M	1.98	$17.38M	$0.21	15.29
Pliant Therapeutics	N/A	N/A	-$149.34M	-$1.84	N/A

Niagen Bioscience has a beta of 2.09, suggesting that its stock price is 109% more volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market.

Niagen Bioscience has a net margin of 14.29% compared to Pliant Therapeutics' net margin of 0.00%. Niagen Bioscience's return on equity of 22.68% beat Pliant Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	14.29%	22.68%	16.23%
Pliant Therapeutics	N/A	-58.11%	-44.37%

Summary

Niagen Bioscience beats Pliant Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Pliant Therapeutics compare to Surrozen?

Surrozen (NASDAQ:SRZN) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Pliant Therapeutics has lower revenue, but higher earnings than Surrozen. Pliant Therapeutics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$7.49M	30.57	-$242.03M	-$37.59	N/A
Pliant Therapeutics	N/A	N/A	-$149.34M	-$1.84	N/A

Surrozen presently has a consensus price target of $42.00, indicating a potential upside of 112.87%. Pliant Therapeutics has a consensus price target of $3.00, indicating a potential upside of 175.23%. Given Pliant Therapeutics' higher probable upside, analysts plainly believe Pliant Therapeutics is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Pliant Therapeutics has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. Surrozen's return on equity of 0.00% beat Pliant Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-4,810.50%	N/A	-154.08%
Pliant Therapeutics	N/A	-58.11%	-44.37%

Surrozen has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market.

66.6% of Surrozen shares are owned by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are owned by institutional investors. 31.7% of Surrozen shares are owned by company insiders. Comparatively, 8.7% of Pliant Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Surrozen and Surrozen both had 3 articles in the media. Pliant Therapeutics' average media sentiment score of 1.08 beat Surrozen's score of 0.63 indicating that Pliant Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surrozen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pliant Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Pliant Therapeutics beats Surrozen on 8 of the 15 factors compared between the two stocks.

Get Pliant Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLRX vs. The Competition

Export

Metric	Pliant Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$66.87M	$3.67B	$6.86B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-0.59	21.48	27.14	23.64
Price / Sales	N/A	169.92	517.01	89.03
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	0.37	7.88	10.28	6.07
Net Income	-$149.34M	$23.86M	$3.60B	$331.99M
7 Day Performance	-5.22%	-3.82%	-1.27%	-0.63%
1 Month Performance	-3.54%	-2.61%	-0.37%	-2.00%
1 Year Performance	-30.57%	32.79%	18.30%	13.62%

Pliant Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLRX Pliant Therapeutics	2.4585 of 5 stars	$1.09 +0.9%	$3.00 +175.2%	-31.4%	$66.87M	N/A	N/A	90	News Coverage Positive News
MGNX MacroGenics	2.642 of 5 stars	$4.44 -1.4%	$5.50 +24.0%	+107.9%	$280.17M	$149.50M	N/A	430	News Coverage
GLSI Greenwich LifeSciences	1.9036 of 5 stars	$18.67 +0.5%	$47.50 +154.5%	+13.0%	$274.78M	N/A	N/A	3	News Coverage Positive News Analyst Forecast Analyst Revision
ALXO ALX Oncology	2.0326 of 5 stars	$2.00 +1.3%	$4.60 +130.6%	+275.9%	$268.45M	N/A	N/A	40
NAGE Niagen Bioscience	4.2586 of 5 stars	$3.37 -3.0%	$10.50 +212.0%	-65.4%	$267.99M	$129.42M	16.02	120	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLRX) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pliant Therapeutics (PLRX) Competitors

PLRX vs. MGNX, GLSI, ALXO, NAGE, and SRZN

How does Pliant Therapeutics compare to MacroGenics?

Summary

How does Pliant Therapeutics compare to Greenwich LifeSciences?

Summary

How does Pliant Therapeutics compare to ALX Oncology?

Summary

How does Pliant Therapeutics compare to Niagen Bioscience?

Summary

How does Pliant Therapeutics compare to Surrozen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX vs. The Competition

Pliant Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pliant Therapeutics (PLRX) Competitors

PLRX vs. MGNX, GLSI, ALXO, NAGE, and SRZN

How does Pliant Therapeutics compare to MacroGenics?

Do institutionals & insiders hold more shares of PLRX or MGNX?

Which has preferable earnings & valuation, PLRX or MGNX?

Which has more volatility and risk, PLRX or MGNX?

Is PLRX or MGNX more profitable?

Do analysts prefer PLRX or MGNX?

Does the media prefer PLRX or MGNX?

Summary

How does Pliant Therapeutics compare to Greenwich LifeSciences?

Which has more volatility & risk, GLSI or PLRX?

Do analysts prefer GLSI or PLRX?

Is GLSI or PLRX more profitable?

Which has higher valuation & earnings, GLSI or PLRX?

Does the media refer more to GLSI or PLRX?

Do institutionals and insiders have more ownership in GLSI or PLRX?

Summary

How does Pliant Therapeutics compare to ALX Oncology?

Which has more risk and volatility, ALXO or PLRX?

Does the media refer more to ALXO or PLRX?

Do analysts prefer ALXO or PLRX?

Do insiders and institutionals have more ownership in ALXO or PLRX?

Is ALXO or PLRX more profitable?

Which has preferable earnings and valuation, ALXO or PLRX?

Summary

How does Pliant Therapeutics compare to Niagen Bioscience?

Do insiders & institutionals believe in NAGE or PLRX?

Does the media favor NAGE or PLRX?

Do analysts prefer NAGE or PLRX?

Which has higher earnings and valuation, NAGE or PLRX?

Which has more risk & volatility, NAGE or PLRX?

Is NAGE or PLRX more profitable?

Summary

How does Pliant Therapeutics compare to Surrozen?

Which has stronger valuation and earnings, SRZN or PLRX?

Do analysts prefer SRZN or PLRX?

Is SRZN or PLRX more profitable?

Which has more volatility & risk, SRZN or PLRX?

Do insiders and institutionals believe in SRZN or PLRX?

Does the media favor SRZN or PLRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX vs. The Competition

Pliant Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools